Prudential plc’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $507K | Buy |
+4,036
| New | +$507K | ﹤0.01% | 629 |
|
|
2024
Q4 | – | Sell |
-21,119
| Closed | -$2.43M | – | 827 |
|
|
2024
Q3 | $2.43M | Buy |
21,119
+5,586
| +36% | +$644K | 0.01% | 372 |
|
|
2024
Q2 | $2.14M | Sell |
15,533
-2,884
| -16% | -$397K | 0.01% | 383 |
|
|
2024
Q1 | $2.54M | Sell |
18,417
-1,514
| -8% | -$209K | 0.02% | 365 |
|
|
2023
Q4 | $2.63M | Sell |
19,931
-606
| -3% | -$79.8K | 0.03% | 358 |
|
|
2023
Q3 | $2.31M | Sell |
20,537
-209
| -1% | -$23.5K | 0.03% | 344 |
|
|
2023
Q2 | $1.96M | Buy |
20,746
+10,591
| +104% | +$999K | 0.02% | 396 |
|
|
2023
Q1 | $1.03M | Buy |
10,155
+4,257
| +72% | +$431K | 0.01% | 544 |
|
|
2022
Q4 | $704K | Buy |
5,898
+3,628
| +160% | +$433K | 0.01% | 666 |
|
|
2022
Q3 | $241K | Buy |
+2,270
| New | +$241K | ﹤0.01% | 769 |
|